Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Dermatologic 1

Conditions

Stomach Neoplasms 1Melanoma 1Lethal Congenital Contracture Syndrome 2 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 73pembrolizumab 70Pemetrexed 63Cisplatin 48Paclitaxel 27Nivolumab 27durvalumab 25osimertinib 24Specimen Handling 24Docetaxel 24Magnetic Resonance Spectroscopy 20Gemcitabine 18atezolizumab 15130-nm albumin-bound paclitaxel 15amivantamab 14Cetuximab 14lazertinib 11Radiotherapy 11Radiosurgery 11Bevacizumab 10Ipilimumab 9cemiplimab 8Taxes 8alectinib 7Ramucirumab 7Observation 7Drug Therapy 7Radiation 6Leucovorin 6Fluorouracil 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Non-Small-Cell Lung × Paroxetine × 30 days × Clear all
NCT07070232 2026-05-22

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

BioNTech SE

Phase 1/2 Recruiting
980 enrolled
DermatologicGastrointestinalThoracic

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung, Melanoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡